---
title: amyloidosis
---

# amyloidosis

- [[rheumatology]]

> [[Systemic diseases with secondary glomerular involvement]]

- [[overview of amyloidosis|overview]] ó°’–

- lightchian disease
- Deposition of misfolded proteins as insoluble fibrils (Î²-pleated sheets) in normal tissues
- æœ€å¸¸è¦‹çš„å››ç¨®ç³»çµ±æ€§åˆ†åˆ¥æ˜¯ ALã€AAã€Ab2Mã€å’Œéºå‚³èˆ‡è€å¹´ç›¸é—œçš„ï¼ˆATTRï¼‰

---

![ğŸ–¼ï¸ Figure: _](https://i.imgur.com/m7pkAYA.png)

---

- [[clinical manifestations of amyloidosis]]
- [[diagnostic studies of amyloidosis]] ó°’—
- [[primary amyloidosis]] (AL)
- [[treatment of amyloidosis]]

- Clearance of amyloid by Ab under study
  - (NEJM 2015;373:1106; Br J Haematol 2020;189:228)
- Cardiac:
  - diuretics;
  - avoid CCB;
  - â†‘ dig toxicity risk (? amyloid binding);
  - anticoag all AF
- Heart, kidney, and liver transplant
  - may be considered in those w/ advanced disease
- Median survival:
  - 5y AL (~6 m if CM);
  - 11y AA;
  - 4y wt ATTR & 2.5y ATTR V122I CM w/o Rx
